arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Celldex Therapeutics, Inc.

CLDX
$28.26 ▼ -1.68 (-5.61%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
68 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Celldex Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B
Dividend Yield —
Revenue Growth -97.0% →
Op. Margin None
ROIC -8.9% ↗
FCF / Share $-0.78 ↗
Trailing P/E —
Price / Book 3.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.00K
↓ -97.0% —
Net Income Profit after all expenses
$-78.69M
↓ -46.3% —
Operating Margin Operating profit as % of sales
-386.2%
↑ +18.1% —
FCF / Share Free cash flow per share
$-0.78
↑ +22.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters